•  
  •  
 

Central Asian Journal of Medicine

Abstract

The purpose of literature review is analytical analysis of the prevalence of ischemic heart disease in the patients with COPD. In this article there is noted significance of the subject area. There are presented detailed data about possible causes for development of this comorbid state, described literature data about possible common pathogenic mechanisms and risk factors. It is emphasized that cardiovascular risk increasing in the patients with COPD, with elevation of severity of disease, growing of the exacerbation frequency. In the rather complete volume there are presented information about role of endothelial dysfunction, chronic systemic inflammation and the system of coagulation and anticoagulation as common pathogenic mechanisms providing development of myocardial infarction in the patients with COPD in this article.

First Page

5

Last Page

13

References

1. Amidzhanova H.G., Kaurov B.A. Aging, age-related diseases and some risk factors for cardiovascular diseases in the elderly and senile. // Clinical medicine. – 2011. - №3. – С. 21-26. 2. Anant R. C. Patel, Beverly S. Kowlessar, Gavin C. Donaldson, Alex J. Mackay, Richa Singh, Siobhan N. George, Davinder S. Garcha, Jadwiga A. Wedzicha and John R. Hurst. Cardiovascular Risk, Myocardial Injury, and Exacerbations of Chronic Obstructive Pulmonary Disease.// Am J Respir Crit Care Med. -2013. –Vol.188 (9). - P.1091–1099. 3. Barr RG, Bluemke DA, Ahmed FS, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. // N Engl J Med. – 2010. Vol.362(3). –P.217–227. 4. Chang CL, Robinson SC, Mills GD, Sullivan GD, Karalus NC, McLachlan JD, Hancox RJ. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. // Thorax. – 2011. – Vol.66. – P.764–768. 5. Chazova E.I., Belenkova Yu.N. Rational pharmacotherapy of cardiovascular diseases. // Practical guide. – 2011. – Т.4. – С.387. 6. Chuchalin A.G., Kutsenko M.A. The paradigm of comorbidity: syntropy of COPD and IHD. // Russian Medical Journal. – 2014. - №5. –С.389. 7. de Miguel Diez J, Chancafe Morgan J, Jimenez Garcia R. The association between COPD and heart failure risk: a review. // Int J Chron Obstruct Pulmon Dis. – 2013. –Vol.8. – P.305–312. 8. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. – 2010. - Vol.137(5). –Р.1091–1097. 9. Ekstrom MP, Hermansson AB, Strom KE. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. //Am J Respir Crit Care Med. – 2013. - Vol.187(7). – Р.715–720. 10. Ferrari R.,Tanni SE, Caram LM, Correa C, Correa CR, Godoy I. Three-year follow-up of Interleukin 6 and C-reactive protein in chronic obstructive pulmonary disease. // Respir Res. – 2013. - Vol. 14. - Р.24 11. Frolov A.G., Nekrasov A.A., Kuznetsov A.N., Shkarin V.V. Predictors of myocardial infarction and features of post-infarction remodeling in patients with chronic obstructive pulmonary disease. // Clinical medicine.– 2011. - №4. –С.66-69.1 12. Garcha DS, Thurston SJ, Patel ARC, Mackay AJ, Goldring JJ, Donaldson GC, McHugh TD, Wedzicha JA. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD.// Thorax. – 2012. - Vol.67. – Р.1075–1080. 13. Garcia-Rio F., Viravitlles M., Soriano B.J. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study.// Respir. Res. -2010. - Vol.1(11). – Р.63. 14. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.// Lancet. – 2012. - Vol.15;380(9859). – Р.2095-2128. 15. Hansel A.L., Walk J.A., Soriano J.B. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis.// Eur. Respir. J. – 2003. - Vol.22 (5). – Р.809-814. 16. Hоiseth AD, Neukamm A, Karlsson BD, Omland T, Brekke PH, Søyseth V. Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease.// Thorax. – 2011. - Vol.66. – Р.775–781. 17. Janda S, Park K, FitzGerald JM, Etminan M, Swiston J. Statins in COPD: a systematic review. Chest. 2009;136(3):734–743. 18. Kuvaev V.S., Bogdanova Yu.V., Selikhova M.A., Kupaev V.I., Davydkin I.L. Microcirculatory disorders in patients with early stages of COPD. // Practical Medicine. – 2014. – №5. –С. 13-15. 19. Laforest L, Roche N, Devouassoux G, Бельхассен M, Chouaid C, Ginoux. Frequency of comorbidities in chronic obstructive pulmonary disease, and impact on all-cause mortality: A population-based cohort study. // Respir Med. -2016. - Vol.117. – Р.33-39. 20. Lozano R., Naghavi M., Foreman K., Lim S., Maclay JD., McAllister DA., Johnston S., Raftis J., McGuinnes C., Deans A., Newby DE., Mills NL., MacNee W. Increased platelet activation in patients with stable and acute exacerbation of COPD. // Thorax. – 2011. - Vol.66. – Р.769–774. 21. Maclay JD, McAllister DA, Mills NL, Paterson FP, Ludlam CA, Drost EM, Newby DE, Macnee W. Vascular dysfunction in chronic obstructive pulmonary disease. // Am J Respir Crit Care Med. – 2009. - Vol.180. – Р.513–520. 22. Marchetti N, Ciccolella DE, Jacobs MR, Crookshank A, Gaughan JP, Kashem MA, Bove AA, Criner GJ. Hospitalized acute exacerbation of COPD impairs flow and nitroglycerin-mediated peripheral vascular dilation. // COPD. – 2011. - Vol.8. – Р.60–65. 23. Mark D. Eisner, Paul D. Blanc, Edward H. Yelin, Patricia P. Katz, Gabriela Sanchez, Carlos Iribarren, Theodore A. Omachi. The influence of anxiety on health outcomes in COPD. // Thorax. – 2010. - Vol.65 (3). – Р.229–234. 24. Matera MG, Calzetta L, Rinaldi B, Cazzola M. Treatment of COPD: moving beyond the lungs. // Curr Opin Pharmacol. – 2012. - Vol.12(3). – Р.315–322. 25. McAllister DA, Maclay JD, Mills NL, Leitch A, Reid P, Carruthers R, O’Connor J, McAlpine L, Chalmers G, Newby DE, et al. Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD.// Eur Respir J. – 2012. - Vol.39. – Р.1097–1103. 26. Miranda Caroline Smith, Jeremy P Wrobel. Epidemiology and clinical impact of major comorbidities in patients with COPD. // Int J Chron Obstruct Pulmon Dis. – 2014. - Vol.9. – Р.871–888. 27. Mitchell GF, Hwang S-J, Vasan RS, Larson MG, Pencina MJ, Hamburg NM, Vita JA, Levy D, Benjamin EJ. Arterial stiffness and cardiovascular events: The Framingham Heart Study.// Circulation. – 2010. - Vol.121. – Р.505–511. 28. Patel ARC, Donaldson GC, Mackay AJ, Wedzicha JA, Hurst JR. The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD.// Chest. – 2012. - Vol.141. – Р.851–857. 29. Patel ARC, Kowlessar BS, Mackay AJ, Donaldson GC, Wedzicha JA, Hurst JR. Relationships between COPD exacerbation frequency and arterial stiffness. //Am J Respir Crit Care Med. – 2012. - Vol.185. – Р.58-54. 30. Polunina O.S., Akhmineeva A.Kh., Voronina L.P., Sevostyanova I.V. Genetic and biochemical parallels in combination of chronic obstructive pulmonary disease and coronary heart disease. // Siberian Medical Journal. – 2013. - №55. –С.37-39. 31. Pribylov S.A., Samosudova L.V., Pribylova N.N., Shabanov E.A. Diastolic dysfunction of the right heart and pulmonary hypertension with a cross phenotype-combination of bronchial asthma and chronic obstructive pulmonary disease according to the register of bronchial asthma in the Kursk region. // Bulletin of the Smolensk State Academy. – 2011. -№16(3). – С.51-57. 32. Rabinovich R. A., MacNee W. Chronic obstructive pulmonary disease and its comorbidities. // Br J Hosp Med (Lond). – 2011. - Vol.72(3). –Р.137-145. 33. Roversi S, Roversi P, Spadafora G, Rossi R, Fabbri LM. Coronary artery disease concomitant with chronic obstructive pulmonary disease. // Eur J Clin Invest. – 2014. - Vol.44. – Р.93–102. 34. Shilov A.M., Tarasenko O.F., Osiya A.O. Features of the treatment of coronary heart disease in combination with chronic obstructive pulmonary disease. // Attending physician. – 2009. -№7. –С.44-48. 35. Shpagina L.A., Kotova O.S., Gerasimenko O.N. Phenotypes and endotypes of professional chronic obstructive pulmonary disease from exposure to toxic gases or inorganic dust. // Herald of modern clinical medicine. – 2017. - №10(5). –С.56—65. 36. Sin D.D., Hye Yun Park, Paul Man S.F. Inhaled corticosteroids for chronic obstructive pulmonary disease. // BMJ. – 2012. - Vol.345. –Р.e6843. 37. Smetneva N.S., Popkova A.S. The study of the cytokine profile in patients with COPD.// Medical advice.- 2013.-№4. –С.108-110. 38. Soodaeva S.K. Free-radical damage mechanisms in diseases of the respiratory system. // Pulmonology. – 2012. -№1. - С.6-10. 39. Stefan MS, Rothberg MB, Priya A, Pekow PS, Au DH, Lindenauer PK. Association between beta-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. // Thorax. – 2012. - Vol.67 (11). – Р.977–984. 40. Thakur N., Blanc PD., Julian LJ., Yelin EH., Katz PP., Sidney S., Iribarren C. Eisner MD. COPD and cognitive impairment: the role of hypoxemia and oxygen therapy. // Int J Chron Obstruct Pulmon Dis. – 2010. - Vol.5. – Р.263-269. 41. Tsiligianni IG, Kosmas E, Van der Molen T, Tzanakis N. Managing comorbidity in COPD: a difficult task. // Curr Drug Targets. – 2013. - Vol.14(2). –Р.158–176. 42. Undas A, Kaczmarek P, Sladek K, Stepien E, Skucha W, Rzeszutko M, Gorkiewicz-Kot I, Tracz W. Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment. //Thromb Haemost. – 2009. - Vol.102. – Р.1176–1182. 43. Vertkin A.L., Skotnikov A.S., Gubzhokova O.M. Comorbidity in chronic obstructive pulmonary disease: the role of chronic systemic inflammation and clinical and pharmacological niches of roflumilast. // Attending physician. - 2013. -№9. –С.143-144. 44. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis.// J Am Coll Cardiol. – 2010. - Vol.55. – Р.1318–1327. 45. Vlachopoulos C., Alexopoulos N, Stefanadis C. Fast in the aorta, slow in the coronaries. // Cardiology. – 2010.- Vol.116. – Р.257–260. 46. Wang MT, Lo YW, Tsai CL, et al. Statin use and risk of COPD exacerbation requiring hospitalization. // Am J Med. – 2013. - Vol.126(7). – Р.598–606.

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.